Search

Background: The clinical effects of smartphone‐based interventions for bipolar disorder (BD) have yet to be established. Objectives: To examine the efficacy of smartphone‐based interventions in BD and how the included studies reported user‐engagement indicators. Methods: We conducted a systematic search on January 24, 2022, in PubMed, Scopus, Embase, APA PsycINFO, and Web of Science. We used random‐effects meta‐analysis to calculate the standardized difference (Hedges' g) in pre‐post change scores between smartphone intervention and control conditions. The study was pre‐registered with PROSPERO (CRD42021226668). Results: The literature search identified 6034 studies. Thirteen articles fulfilled the selection criteria. We included seven RCTs and performed meta‐analyses comparing the pre‐post change in depressive and (hypo)manic symptom severity, functioning, quality of life, and perceived stress between smartphone interventions and control conditions. There was significant heterogeneity among studies and no meta‐analysis reached statistical significance. Results were also inconclusive regarding affective relapses and psychiatric readmissions. All studies reported positive user‐engagement indicators. Conclusion: We did not find evidence to support that smartphone interventions may reduce the severity of depressive or manic symptoms in BD. The high heterogeneity of studies supports the need for expert consensus to establish ideally how studies should be designed and the use of more sensitive outcomes, such as affective relapses and psychiatric hospitalizations, as well as the quantification of mood instability. The ISBD Big Data Task Force provides preliminary recommendations to reduce the heterogeneity and achieve more valid evidence in the field. [ABSTRACT FROM AUTHOR]

Doxorubicin is a common treatment for breast cancer. However, not all patients respond to this drug, which sometimes causes life‐threatening side effects. Accurately anticipating doxorubicin‐resistant patients would therefore permit to spare them this risk while considering alternative treatments without delay. Stratifying patients based on molecular markers in their pretreatment tumors is a promising approach to advance toward this ambitious goal, but single‐gene gene markers such as HER2 expression have not shown to be sufficiently predictive. The recent availability of matched doxorubicin‐response and diverse molecular profiles across breast cancer patients permits now analysis at a much larger scale. 16 machine learning algorithms and 8 molecular profiles are systematically evaluated on the same cohort of patients. Only 2 of the 128 resulting models are substantially predictive, showing that they can be easily missed by a standard‐scale analysis. The best model is classification and regression tree (CART) nonlinearly combining 4 selected miRNA isoforms to predict doxorubicin response (median Matthew correlation coefficient (MCC) and area under the curve (AUC) of 0.56 and 0.80, respectively). By contrast, HER2 expression is significantly less predictive (median MCC and AUC of 0.14 and 0.57, respectively). As the predictive accuracy of this CART model increases with larger training sets, its update with future data should result in even better accuracy. [ABSTRACT FROM AUTHOR]

Objective: To evaluate whether accelerated brain aging occurs in individuals with mood or psychotic disorders. Methods: A systematic review following PRISMA guidelines was conducted. A meta‐analysis was then performed to assess neuroimaging‐derived brain age gap in three independent groups: (1) schizophrenia and first‐episode psychosis, (2) major depressive disorder, and (3) bipolar disorder. Results: A total of 18 papers were included. The random‐effects model meta‐analysis showed a significantly increased neuroimaging‐derived brain age gap relative to age‐matched controls for the three major psychiatric disorders, with schizophrenia (3.08; 95%CI [2.32; 3.85]; p < 0.01) presenting the largest effect, followed by bipolar disorder (1.93; [0.53; 3.34]; p < 0.01) and major depressive disorder (1.12; [0.41; 1.83]; p < 0.01). The brain age gap was larger in older compared to younger individuals. Conclusion: Individuals with mood and psychotic disorders may undergo a process of accelerated brain aging reflected in patterns captured by neuroimaging data. The brain age gap tends to be more pronounced in older individuals, indicating a possible cumulative biological effect of illness burden. [ABSTRACT FROM AUTHOR]

Molecular docking predicts whether and how small molecules bind to a macromolecular target using a suitable 3D structure. Scoring functions for structure‐based virtual screening primarily aim at discovering which molecules bind to the considered target when these form part of a library with a much higher proportion of non‐binders. Classical scoring functions are essentially models building a linear mapping between the features describing a protein–ligand complex and its binding label. Machine learning, a major subfield of artificial intelligence, can also be used to build fast supervised learning models for this task. In this review, we analyzed such machine‐learning scoring functions for structure‐based virtual screening in the period 2015–2019. We have discussed what the shortcomings of current benchmarks really mean and what valid alternatives have been employed. The latter retrospective studies observed that machine‐learning scoring functions were substantially more accurate, in terms of higher hit rates and potencies, than the classical scoring functions they were compared to. Several of these machine‐learning scoring functions were also employed in prospective studies, in which mid‐nanomolar binders with novel chemical structures were directly discovered without any potency optimization. We have thus highlighted the codes and webservers that are available to build or apply machine‐learning scoring functions to prospective structure‐based virtual screening studies. A discussion of prospects for future work completes this review. This article is categorized under:Computer and Information Science > Chemoinformatics [ABSTRACT FROM AUTHOR]

The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already‐approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechanism of action of mebendazole, an antihelminthic drug, currently repurposed in the treatment of brain tumors. First, we confirmed that mebendazole decreased the viability of glioblastoma cells in vitro (IC50 values ranging from 288 nm to 2.1 µm). Our in silico approach unveiled 21 putative molecular targets for mebendazole, including 12 proteins significantly upregulated at the gene level in glioblastoma as compared to normal brain tissue (fold change > 1.5; P < 0.0001). Validation experiments were performed on three major kinases involved in cancer biology: ABL1, MAPK1/ERK2, and MAPK14/p38α. Mebendazole could inhibit the activity of these kinases in vitro in a dose‐dependent manner, with a high potency against MAPK14 (IC50 = 104 ± 46 nm). Its direct binding to MAPK14 was further validated in vitro, and inhibition of MAPK14 kinase activity was confirmed in live glioblastoma cells. Consistent with biophysical data, molecular modeling suggested that mebendazole was able to bind to the catalytic site of MAPK14. Finally, gene silencing demonstrated that MAPK14 is involved in glioblastoma tumor spheroid growth and response to mebendazole treatment. This study thus highlighted the role of MAPK14 in the anticancer mechanism of action of mebendazole and provides further rationale for the pharmacological targeting of MAPK14 in brain tumors. It also opens new avenues for the development of novel MAPK14/p38α inhibitors to treat human diseases. [ABSTRACT FROM AUTHOR]

Molecular docking can be used to predict how strongly small‐molecule binders and their chemical derivatives bind to a macromolecular target using its available three‐dimensional structures. Scoring functions (SFs) are employed to rank these molecules by their predicted binding affinity (potency). A classical SF assumes a predetermined theory‐inspired functional form for the relationship between the features characterizing the structure of the protein–ligand complex and its predicted binding affinity (this relationship is almost always assumed to be linear). Recent years have seen the prosperity of machine‐learning SFs, which are fast regression models built instead with contemporary supervised learning algorithms. In this review, we analyzed machine‐learning SFs for drug lead optimization in the 2015–2019 period. The performance gap between classical and machine‐learning SFs was large and has now broadened owing to methodological improvements and the availability of more training data. Against the expectations of many experts, SFs employing deep learning techniques were not always more predictive than those based on more established machine learning techniques and, when they were, the performance gain was small. More codes and webservers are available and ready to be applied to prospective structure‐based drug lead optimization studies. These have exhibited excellent predictive accuracy in compelling retrospective tests, outperforming in some cases much more computationally demanding molecular simulation‐based methods. A discussion of future work completes this review. This article is categorized under:Computer and Information Science > Chemoinformatics [ABSTRACT FROM AUTHOR]

Objectives: The International Society for Bipolar Disorders Big Data Task Force assembled leading researchers in the field of bipolar disorder (BD), machine learning, and big data with extensive experience to evaluate the rationale of machine learning and big data analytics strategies for BD. Method: A task force was convened to examine and integrate findings from the scientific literature related to machine learning and big data based studies to clarify terminology and to describe challenges and potential applications in the field of BD. We also systematically searched PubMed, Embase, and Web of Science for articles published up to January 2019 that used machine learning in BD. Results: The results suggested that big data analytics has the potential to provide risk calculators to aid in treatment decisions and predict clinical prognosis, including suicidality, for individual patients. This approach can advance diagnosis by enabling discovery of more relevant data‐driven phenotypes, as well as by predicting transition to the disorder in high‐risk unaffected subjects. We also discuss the most frequent challenges that big data analytics applications can face, such as heterogeneity, lack of external validation and replication of some studies, cost and non‐stationary distribution of the data, and lack of appropriate funding. Conclusion: Machine learning‐based studies, including atheoretical data‐driven big data approaches, provide an opportunity to more accurately detect those who are at risk, parse‐relevant phenotypes as well as inform treatment selection and prognosis. However, several methodological challenges need to be addressed in order to translate research findings to clinical settings. [ABSTRACT FROM AUTHOR]

Molecular target prediction can provide a starting point to understand the efficacy and side effects of phenotypic screening hits. Unfortunately, the vast majority of in silico target prediction methods are not available as web tools. Furthermore, these are limited in the number of targets that can be predicted, do not estimate which target predictions are more reliable and/or lack comprehensive retrospective validations. We present MolTarPred (http://moltarpred.marseille.inserm.fr/), a user‐friendly web tool for predicting protein targets of small organic compounds. It is powered by a large knowledge base comprising 607,659 compounds and 4,553 macromolecular targets collected from the ChEMBL database. In about 1 min, the predicted targets for the supplied molecule will be listed in a table. The chemical structures of the query molecule and the most similar compounds annotated with the predicted target will also be shown to permit visual inspection and comparison. Practical examples of the use of MolTarPred are showcased. MolTarPred is a new resource for scientists that require a more complete knowledge of the polypharmacology of a molecule. The introduction of a reliability score constitutes an attractive functionality of MolTarPred, as it permits focusing experimental confirmatory tests on the most reliable predictions, which leads to higher prospective hit rates. [ABSTRACT FROM AUTHOR]

Many increasingly prevalent diseases share a common risk factor: age. However, little is known about pharmaceutical interventions against aging, despite many genes and pathways shown to be important in the aging process and numerous studies demonstrating that genetic interventions can lead to a healthier aging phenotype. An important challenge is to assess the potential to repurpose existing drugs for initial testing on model organisms, where such experiments are possible. To this end, we present a new approach to rank drug-like compounds with known mammalian targets according to their likelihood to modulate aging in the invertebrates Caenorhabditis elegans and Drosophila. Our approach combines information on genetic effects on aging, orthology relationships and sequence conservation, 3D protein structures, drug binding and bioavailability. Overall, we rank 743 different drug-like compounds for their likelihood to modulate aging. We provide various lines of evidence for the successful enrichment of our ranking for compounds modulating aging, despite sparse public data suitable for validation. The top ranked compounds are thus prime candidates for in vivo testing of their effects on lifespan in C. elegans or Drosophila. As such, these compounds are promising as research tools and ultimately a step towards identifying drugs for a healthier human aging. [ABSTRACT FROM AUTHOR]

Docking tools to predict whether and how a small molecule binds to a target can be applied if a structural model of such target is available. The reliability of docking depends, however, on the accuracy of the adopted scoring function (SF). Despite intense research over the years, improving the accuracy of SFs for structure-based binding affinity prediction or virtual screening has proven to be a challenging task for any class of method. New SFs based on modern machine-learning regression models, which do not impose a predetermined functional form and thus are able to exploit effectively much larger amounts of experimental data, have recently been introduced. These machine-learning SFs have been shown to outperform a wide range of classical SFs at both binding affinity prediction and virtual screening. The emerging picture from these studies is that the classical approach of using linear regression with a small number of expert-selected structural features can be strongly improved by a machine-learning approach based on nonlinear regression allied with comprehensive data-driven feature selection. Furthermore, the performance of classical SFs does not grow with larger training datasets and hence this performance gap is expected to widen as more training data becomes available in the future. Other topics covered in this review include predicting the reliability of a SF on a particular target class, generating synthetic data to improve predictive performance and modeling guidelines for SF development. WIREs Comput Mol Sci 2015, 5:405-424. doi: 10.1002/wcms.1225 For further resources related to this article, please visit the . [ABSTRACT FROM AUTHOR]

There is a growing body of evidence showing that machine learning regression results in more accurate structure-based prediction of protein-ligand binding affinity. Docking methods that aim at optimizing the affinity of ligands for a target rely on how accurate their predicted ranking is. However, despite their proven advantages, machine-learning scoring functions are still not widely applied. This seems to be due to insufficient understanding of their properties and the lack of user-friendly software implementing them. Here we present a study where the accuracy of AutoDock Vina, arguably the most commonly-used docking software, is strongly improved by following a machine learning approach. We also analyse the factors that are responsible for this improvement and their generality. Most importantly, with the help of a proposed benchmark, we demonstrate that this improvement will be larger as more data becomes available for training Random Forest models, as regression models implying additive functional forms do not improve with more training data. We discuss how the latter opens the door to new opportunities in scoring function development. In order to facilitate the translation of this advance to enhance structure-based molecular design, we provide software to directly re-score Vina-generated poses and thus strongly improve their predicted binding affinity. The software is available at http://istar.cse.cuhk.edu.hk/rf-score-3.tgz and http://crcm. marseille.inserm.fr/fileadmin/rf-score-3.tgz [ABSTRACT FROM AUTHOR]

Finding a set of molecules, which closely resemble a given lead molecule, from a database containing potentially billions of chemical structures is an important but daunting problem. Similar molecular shapes are particularly important, given that in biology small organic molecules frequently act by binding into a defined and complex site on a macromolecule. Here, we present a new method for molecular shape comparison, named ultrafast shape recognition (USR), capable of screening billions of compounds for similar shapes using a single computer and without the need of aligning the molecules before testing for similarity. Despite its extremely fast comparison rate, USR will be shown to be highly accurate at describing, and hence comparing, molecular shapes. © 2007 Wiley Periodicals, Inc. J Comput Chem, 2007 [ABSTRACT FROM AUTHOR]